Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response

@article{Sarkaria2006UseOA,
  title={Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response},
  author={Jann N. Sarkaria and Brett L. Carlson and Mark A. Schroeder and Patrick T. Grogan and Paul D Brown and Caterina Giannini and Karla V. Ballman and Gaspar J. Kitange and Abjahit Guha and Ajay Pandita and Charles David James},
  journal={Clinical Cancer Research},
  year={2006},
  volume={12},
  pages={2264 - 2271}
}
Purpose: The influence of epidermal growth factor receptor (EGFR) amplification on glioblastoma patient prognosis following definitive radiotherapy has been extensively investigated in clinical studies, and yet the relationship between EGFR status and radiation response remains unclear. The intent of the current study was to address this relationship using several EGFR-amplified glioblastoma xenografts in an orthotopic athymic mouse model. Experimental Design: We examined the effect of… 
View on AACR
clincancerres.aacrjournals.org
239 Citations
Highly Influential Citations
10
Background Citations
72
Methods Citations
48
Results Citations
4

239 Citations

Citation Type

Citation Type

NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification
TLDR
Results show that NT113 is active against GBM xenografts in which wild-type EGFR or EGFRvIII is highly expressed, and western blot analysis results indicated thatNT113 has inhibitory activity, both in vivo and in vitro, on ERBB family member phosphorylation, as well as on theosphorylation of downstream signaling mediator Akt.
Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results
TLDR
The data suggest that different classes of EGFR inhibitors may have a different potential to improve local tumour control after fractionated irradiation, and multiple radiobiological mechanisms might contribute to the observed effects.
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
TLDR
This study identified two erlotinib-sensitive glioblastoma xenografts, with the common molecular characteristics shared by each being the expression of wild-type PTEN in combination with theexpression of amplified and aberrant EGFR.
EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts
TLDR
EGFR targeting through tyrosine kinase inhibition appears to be a promising new approach in the treatment of EGFR‐driven glioma, particularly in combination with radiation therapy.
Epidermal Growth Factor Receptor activity is elevated in glioma cancer stem cells and is required to maintain chemotherapy and radiation resistance
TLDR
It is shown that both canine and human glioma cell lines contain a small population of cancer stem cells (CSCs), and the important role of the epidermal growth factor receptor (EGFR) pathway in canine CSCs is highlighted, enabling this resistant, tumourigenic population of cells to be effectively targeted by conventional therapies.
Epidermal growth factor receptor activity is elevated in glioma cancer stem cells and is required to maintain chemotherapy and radiation resistance
TLDR
It is shown that both canine and human glioma cell lines contain a small population of cancer stem cells (CSCs), and the important role of the epidermal growth factor receptor (EGFR) pathway in canine CSCs is highlighted, enabling this resistant, tumourigenic population of cells to be effectively targeted by conventional therapies.
Combining molecular targeted agents with radiation therapy for malignant gliomas
TLDR
Much remains to be learned regarding the optimal combination of targeted agents with conventional chemoradiation, including the use of multipathways-targeted therapies, the selection of patients who may benefit from combined treatments based on molecular biomarkers, and the verification of effective blockade of signaling pathways.
Small Molecule Therapeutics NT 113 , a Pan-ERBB Inhibitor with High Brain Penetrance , Inhibits the Growth of Glioblastoma Xenografts with EGFR Ampli fi cation
TLDR
Results show that NT113 is active against GBM xenografts in which wild-type EGFR or EGFRvIII is highly expressed, and western blot analysis results indicated thatNT113 has inhibitory activity, both in vivo and in vitro, on ERBB family member phosphorylation, as well as on theosphorylation of downstream signaling mediator Akt.
Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM
TLDR
The data identify ALDH levels as a biomarker of GBM cells with high invasive potential, altered oxidative stress, and resistance to EGFR inhibition, and reveal a therapeutic target whose inhibition should limit GBM invasion.
Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
TLDR
Coexpression of VEGFR2 expression by GBM cells in which EGFR signaling is activated may contribute to the aggressive nature of these cells and support cell cycle progression and prevents cellular senescence.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.
TLDR
Because the heterotopic-to-orthotopic transfer and propagation of glioblastoma multiforme preserves the receptor tyrosine kinase (RTK) gene amplification of patient tumors, this approach should facilitate investigations for determining the extent to which RTK amplification status influences tumor response to RTK-directed therapies.
Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development.
TLDR
The capacity of EGFR inhibitors to modulate cellular and overall tumor response to ionizing radiation and shows great promise in the treatment of a variety of solid tumors that overexpress this receptor.
Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR
TLDR
Analysis of EGFR copy number and EGFR mutation status in 11 patient tumors and their corresponding xenografts indicated that selection for EGFR amplification is an in vivo phenomenon and showed that the selection of amplified mutant EGFR over amplified wild‐type EGFR as a Xenograft occurred rapidly and completely during tumor propagation.
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.
TLDR
It is demonstrated that gliomas with amplification of the EGFR gene are capable of establishing in culture but that the amplified rearranged genes are not maintained and suggest that high expression and structural abnormalities of EGFR proteins generated by amplification and rearrangement of theEGFR gene provide a growth advantage for glioma in vivo but not in vitro.
EGFR overexpression and radiation response in glioblastoma multiforme.
Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor.
TLDR
The experiments demonstrate for the first time that radiosensitization of malignant glioma cells through disruption of EGFR function may be achieved by genetic therapy approaches and suggest the disruption of a major cytoprotective response involving EGFR and its downstream effectors, such as mitogen-activated protein kinase.
Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').
Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
TLDR
Findings suggest that IGFR-I signaling through phosphoinositide 3-kinase may represent a novel and potentially important mechanism of resistance to anti-EGFR therapy.
Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation.
Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774).
TLDR
Tarceva is a novel inhibitor of the EGFR TK which has shown promising activity in initial studies and is currently undergoing full development as an anticancer drug.
...
1
2
3
4
5
...